TrialBritish journal of pharmacology2017

Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk.

Kunio Sugahara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.